A2 dairy and the omega-3 supplements it sells are under scrutiny after researchers found the drugs could worsen symptoms of the degenerative disease in people who eat the products.
A2 said the compounds were not found to be harmful in healthy people, though it has tested the compounds for safety in people with Alzheimer’s disease and other neurological disorders.
It also said the company had received no requests to pull the products from the market.
The company said in a statement that it “strongly encourages consumers to seek medical advice and not to alter the formulation of their own product.”
The FDA said it has been investigating the matter.
Researchers from the Mayo Clinic in Rochester, Minnesota, and Johns Hopkins University in Baltimore, Maryland, found A2’s products, including a formulation called A2Pro, increase the risk of Alzheimer’s-like symptoms in people taking the drugs.
Researchers also found that people taking A2 had higher levels of beta-amyloid protein, a protein that causes Alzheimer’s.
The study, published online Sept. 18 in the journal JAMA Neurology, found that the drug increases beta-ameryloid, a form of amyloid plaques that accumulate in the brains of people with dementia.
People who take A2 are also more likely to develop beta-plaques and higher levels in the brain of people who develop Alzheimer’s later in life, researchers said.
A 2D map of A2 and Alzheimer’s, with the Mayo Center for Alzheimer’s Research at the center.
A second study led by Dr. Jeffrey B. Davis of the Mayo Institute for Clinical and Experimental Therapeutics found that beta-mercaptoethanol, which is made by A2, also increases beta amyloids.
Beta-amys is a protein found in the amylopectin protein in the body.
Beta amylol is a beta-synthase enzyme that makes amylase, the enzyme that breaks down amylates, or amylating factors, in proteins.
Beta Mercaptoethylene is a form that A2 makes from its own production of A1, according to the Mayo study.
Beta Amyloid is a type of protein found primarily in the form of beta amines, which are proteins found in proteins such as cholesterol.
In the Mayo analysis, beta amids were more common in people whose brains were not showing signs of Alzheimer and in people in the middle of their dementia.
A study published this week in the Journal of Alzheimer, Dement, and Alzheimer Disease found that A1s were more prevalent in people diagnosed with Alzheimer in the first 10 years of their disease, even after adjusting for other factors such as age, gender and other factors.
A1 amylases are found in some cells of the brain, including the hippocampus and other areas involved in memory.
Beta, a precursor to beta amides, are also found in brain cells and are produced by other cell types, such as white blood cells.
The Mayo study also found A1 levels were lower in people treated with beta amidases compared with people who didn’t take the drugs, the Mayo researchers said in their study.
Mayo researchers also found a link between beta-1-tetrahydrofolate reductase (BTRE) and beta- amylotic plaques in the hippocampus.
They did not say how A2 may be linked to Alzheimer, though the researchers say the findings suggest A2 could be the drug that could prevent dementia.
The researchers found that BTRE increases beta plaques and beta amyoid levels in people on A2.
A previous study found that a beta 1-tererofolates derivative called A3 was associated with the same effect.
A3 is a non-steroidal anti-inflammatory drug used to treat arthritis and joint pain.
It has been linked to cognitive decline and dementia, but the drug is still not approved for use in the United States for people with moderate to severe dementia.
In a separate study published last month in the Archives of Internal Medicine, a Mayo team led by Andrew P. Chiang of the Department of Health Policy and Management at the Mayo Children’s Hospital found that individuals who were taking A1 were less likely to have Alzheimer’s symptoms than those who weren’t.
The results suggest that individuals taking A3 may be at risk for dementia, the researchers said, and that people who take both A1 and A3 could be at higher risk for Alzheimer.